Wellmarker Bio Overview
- Founded
- 2016
- Status
- Private
- Latest Deal Type
- Series B
- Latest Deal Amount
- $15.4M
- Investors
- 17
Wellmarker Bio General Information
Description
Developer of anticancer drugs intended to address unmet medical needs. The company develops predictive biomarkers and first-in-class drugs through profound research know-hows and clinical information, thereby enabling medical practitioners to bring a better outcome and contribute to the healthy life of patients.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Primary Office
- 7th floor, NH Songpa nonghyup Building
- 155 Songpa-daero, Songpa-gu
- Seoul, 05855
- South Korea
+82 00-0000-0000
Wellmarker Bio Timeline
Wellmarker Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series B) | 08-Jul-2019 | $15.4M | 000.00 | Completed | Pre-Clinical Trials | |
| 2. Early Stage VC (Series A) | 08-Oct-2018 | 000.00 | 000.00 | Completed | Pre-Clinical Trials | |
| 1. Seed Round | 01-Apr-2018 | $4.34M | $4.34M | Completed | Pre-Clinical Trials |
Wellmarker Bio Executive Team (1)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Jin Dong-Hoon | Founder & Chief Executive Officer |
Wellmarker Bio Investors (17)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Brick Investment Partners | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| Cytogen (south Korea) | Venture Capital | Minority | 000 0000 | 000000 0 | |
| HB Investments | Venture Capital | Minority | 000 0000 | 000000 0 | |
| NH Investment & Securities | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| Orbit Venture Partners | Venture Capital | Minority | 000 0000 | 000000 0 |